Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766831 | 0.82 | CYP1A2 (0.61) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL6764315 | 0.80 | KDM4E (0.58) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL24273106 | 0.77 | PTGER4 (0.58) | SMN1; SMN2MEN1KMT2ATDP1KDM4E | |
| SCHEMBL6762228 | 0.76 | ACKR3 (0.47) | KDM4E | |
| SCHEMBL6763555 | 0.76 | CNR1 (0.56) | ALDH1A1KDM4E | |
| SCHEMBL6764331 | 0.76 | KDM4E (0.46) | SMN1; SMN2HPGDKDM4EGLATP53 | |
| SCHEMBL10856486 | 0.74 | MEN1 (0.70) | SMN1; SMN2MEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL6763004 | 0.73 | MEN1 (0.47) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6762478 | 0.73 | USP30 (0.44) | HPGDKDM4EGLATP53 | |
| SCHEMBL14553827 | 0.72 | MEN1 (0.67) | SMN1; SMN2MEN1KMT2AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | claimed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | claimed |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | SMN1; SMN2 2436/4885MEN1 2433/4885KMT2A 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.